Get the Stockscreener App
0.7271
6.50%
0.0444
Adicet Bio Inc stock is traded at $0.7271, with a volume of 708.86K.
It is up +6.50% in the last 24 hours and down -3.31% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.6827
Open:
$0.6873
24h Volume:
708.86K
Relative Volume:
1.45
Market Cap:
$60.53M
Revenue:
$24.99M
Net Income/Loss:
$-118.64M
P/E Ratio:
-0.555
EPS:
-1.31
Net Cash Flow:
$-100.25M
1W Performance:
+11.01%
1M Performance:
-3.31%
6M Performance:
-25.30%
1Y Performance:
-52.79%
1-Day Range:
$0.6873
$0.75
1-Week Range:
$0.6355
$0.75
52-Week Range:
$0.4471
$1.63
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.7271 | 60.36M | 24.99M | -118.64M | -100.25M | -1.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Fibonacci Support Holding Strong in Adicet Bio Inc.Weekly Trade Report & AI Optimized Trade Strategies - news-j.co.kr
Will Adicet Bio Inc. rebound enough to break even2025 Geopolitical Influence & Consistent Profit Trade Alerts - Newser
Will earnings trigger a reversal in Adicet Bio Inc.Market Rally & Real-Time Volume Analysis Alerts - Newser
Is Adicet Bio Inc. trending in predictive chart modelsOil Prices & Detailed Earnings Play Strategies - Newser
Pattern recognition hints at Adicet Bio Inc. upsideJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Key resistance and support levels for Adicet Bio Inc.July 2025 Market Mood & Low Drawdown Investment Strategies - Newser
What data driven models say about Adicet Bio Inc.’s futureQuarterly Investment Review & Stepwise Entry/Exit Trade Alerts - Newser
How high can Adicet Bio Inc. stock price go in 2025Quarterly Profit Review & Short-Term High Return Strategies - Newser
Is Adicet Bio Inc. showing insider buying2025 Breakouts & Breakdowns & Short-Term Trading Opportunity Alerts - kangso.co.kr
Will Adicet Bio Inc. benefit from sector rotationJuly 2025 Patterns & Verified Entry Point Signals - newsyoung.net
Statistical indicators supporting Adicet Bio Inc.’s strengthJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Custom watchlist performance reports with Adicet Bio Inc.July 2025 Selloffs & Low Drawdown Investment Strategies - Newser
Recovery Signals Appearing in Adicet Bio Inc. Charts2025 Breakouts & Breakdowns & Capital Efficiency Focused Strategies - beatles.ru
How Adicet Bio Inc. stock performs during market volatilityTrade Risk Summary & AI Driven Stock Price Forecasts - sundaytimes.kr
MaxCyte Signs Platform License Agreement With Adicet Bio - Technology Networks
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
Adicet Bio’s SWOT analysis: cell therapy firm’s stock faces clinical hurdles - Investing.com
Adicet Bio’s Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks
Adicet Bio (ACET) Upgraded to Buy: Here's Why - MSN
Adicet Bio Inc. stock volume spike explained2025 Major Catalysts & Long Hold Capital Preservation Plans - Newser
Citizens JMP maintains Market Perform rating on Adicet Bio stock By Investing.com - Investing.com South Africa
Citizens JMP maintains Market Perform rating on Adicet Bio stock - Investing.com India
Chart Analysts Warn of Resistance Near Adicet Bio Inc. PriceSector Rotation Based Trading Opportunities Identified - beatles.ru
What makes Adicet Bio Inc. stock price move sharplyFree Top 5 Picks of the Week - thegnnews.com
What is the next catalyst for Adicet Bio Inc.Squeeze Play Stock Candidates - mustnews.co.kr
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
Adicet Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
Signal strength of Adicet Bio Inc. stock in tech scannersMarket Opportunity Tracker for Swing Traders - Newser
MaxCyte signs platform license agreement with Adicet Bio - MSN
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Adicet Bio Reports Q2 2025 Financial Results - The Globe and Mail
Adicet Bio: Strategic Advancements and Financial Prudence Drive Analyst's Buy Rating - AInvest
Adicet Bio: Strategic Advancements and Financial Prudence Drive Buy Rating - TipRanks
Adicet Bio Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Adicet Bio (ACET) Q2 Loss Widens 3% - AOL.com
Adicet Bio reports Q2 EPS (34c), consensus (30c) - TipRanks
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference - BioSpace
MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement - AInvest
MaxCyte Inks Strategic Platform License with Adicet Bio, Entitled to Licensing Fees and Revenue - AInvest
Maxcyte signs platform license agreement with Adicet Bio - MarketScreener
MaxCyte Signs Platform License Agreement with Adicet Bio - The Manila Times
MaxCyte, Adicet Bio Sign Strategic Platform License Agreement - AInvest
MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Adicet's Cancer Treatment Innovation - Stock Titan
What are Adicet Bio Inc. company’s key revenue driversAchieve rapid portfolio growth with smart picks - Jammu Links News
Is it the right time to buy Adicet Bio Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What markets is Adicet Bio Inc. expanding into Is AMZE stock a good long term investment optionTriple-digit return opportunities - Jammu Links News
What drives Adicet Bio Inc. stock priceBuild a diversified portfolio for steady growth - Jammu Links News
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):